King Willem-Alexander of the Netherlands to open new headquarters of Applikon Biotechnology

Published: 6-Nov-2013
Manufacturing Pharmaceutical

New facility includes offices, R&D laboratories and a state-of-the-art warehouse

The new headquarters of Applikon Biotechnology in Delft, The Netherlands will be opened by His Majesty King Willem-Alexander of the Netherlands on 4 December.

The new production facility for the Dutch manufacturer of bioreactor systems for research and production has been operational for several months and the festivities will officially mark this further step in the development and growth of the company.

The 3,700m2 facility on the Technopolis high-tech science park in Delft includes offices, R&D laboratories, a workshop and state-of-the-art warehouse. Approximately 100 people are based on the site.

Construction began about 12 months ago.

Applikon Biotechnology is now able to provide a complete range of bioreactor systems ranging from microlitre research volumes up to 15,000 litre production systems for pharmaceutical and biotechnological applications.

The firm has subsidiaries in the US, UK and China.

  • Companies:
  • Applikon Biotechnology
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

Read more
The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
  5. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports
Manufacturing

Microbioreactor rapidly handles microbial strains, clone libraries and cells

Micro-Matrix offers 24 independent bioreactors in microtitre plate footprint
Manufacturing

Applikon Biotechnology officially opens a new production facility in China

Event will be combined with a scientific seminar on bioreactor technology innovations
Manufacturing

Applikon Biotechnology starts construction of new facility in Delft

The building will accommodate 100 people and be completed next summer
Manufacturing

ACG expands global footprint with new capsule manufacturing facility in Thailand

New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Manufacturing

Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary

The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
Subscribe now